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doi:10.101High-Dose Iodine-131-Metaiodobenzylguanidine
with Haploidentical Stem Cell Transplantation
and Posttransplant Immunotherapy in Children
with Relapsed/Refractory Neuroblastoma
Jacek Toporski,1 Michael Garkavij,2 Jan Tennvall,2 Ingrid Øra,1 Katarina Sjo¨green Gleisner,3
Josefina H. Dykes,4,5 Stig Lenhoff,6 Gunnar Juliusson,6,7 Stefan Scheding,6,7
Dominik Turkiewicz,1,8 Albert N. Bekassy1131We evaluated the feasibility and efficacy of using high-dose iodine-131-metaiodobenzylguanidine ( I-MIBG)
followed by reduced-intensity conditioning (RIC) and transplantation of T cell-depleted haploidentical
peripheral blood stem cells (designated haplo-SCT) to treat relapsing/refractory neuroblastoma (RRNB).
Five RRNB patients were enrolled: 4 with relapse (3 after autologous SCT) and 1 with induction therapy fail-
ure. The preparative regimen included high-dose 131I-MIBG on day –20, followed by fludarabine (Flu), thio-
tepa, and melphalan (Mel) from day –8 to –1. Granulocyte-colony stimulating factor (G-CSF)-mobilized, T
cell-depleted haploidentical paternal stem cells were infused on day 0 together with cultured donor mesen-
chymal stem cells. A single dose of rituximab was given on day11. After cessation of short immunosuppres-
sion (mycophenolate, OKT3), 4 children received donor lymphocyte infusion (DLI). 131I-MIBG infusion and
RIC were well tolerated. All patients engrafted. No primary acute graft-versus-host disease (aGVHD) was
observed. Four children developed aGVHD after DLI and were successfully treated. Analysis of immunologic
recovery showed fast reappearance of potentially immunocompetent natural killer (NK) and T cells, which
might have acted as effector cells responsible for the graft-versus-tumor (GVT) effect. Two children are alive
and well, with no evidence of disease 40 and 42 months after transplantation. One patient experienced late
progression with new bone lesions (sternum) 38 months after haplo-SCT, and is being treated with local ir-
radiation and reinstituted DLI. One patient rejected the graft, was rescued with autologous backup, and died
of progressive disease 5 months after transplantation. Another child relapsed 7 months after transplantation
and died 5 months later. High-dose 131I-MIBG followed by RIC and haplo-SCT for RRNB is feasible and prom-
ising, because 2 of 5 children on that regimen achieved long-lasting remission. Further studies are needed to
evaluate targeted therapy and immune-mediated tumor control in high-risk neuroblastoma.
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The prognosis for relapsing/refractory neuroblas-
toma (RRNB) remains dismal, with a 5-year disease-
free survival (DFS) of\20%, and no effective salvage
treatment has been identified so far. Palliation is often
the sole option for recurrent disease after myeloabla-
tive (MA) treatment, because salvage therapy may
not be feasible or justified because of no realistic
chance for cure [1,2]. Treatment of RRNB is still ex-
perimental, and focused on introducing novel cyto-
toxic and/or tumor-targeted biological agents.
The norepinephrine analogmetaiodobenzylguani-
dine (MIBG) is selectively accumulated in sympathetic
nervous tissue, and several studies have suggested that
treatment with iodine-131-labled MIBG (131I-MIBG)1077
1078 Biol Blood Marrow Transplant 15:1077-1085, 2009J. Toporski et al.induces remission in NB, even in advanced cases.
Duration of remission remains the primary concern,
and the possibility of incorporating131I-MIBG into
multimodal therapy for RRNB has been proposed
[3]. An investigation of high-risk patients showed
that a combination of high-dose131I-MIBG, high-
dose chemotherapy, and autologous hematopoietic
stem cell transplantation (ASCT) was practicable and
associated with limited toxicity [4,5]. However, only
36% of the patients responded, and the 3-year event-
free survival (EFS) rate was 0.31 6 0.10.
Studies have not shown any advantage in using
HLA-identical donors for allogeneic stem cell trans-
plantation (allo-SCT) to treat high-risk NB [6-8].
Also, it has been postulated that absence of graft-
versus-host disease (GVHD) in allo-SCT is a major
obstacle to an antitumor effect. Haploidentical stem
cell transplantation (haplo-SCT) for treatment of
malignant diseases has become an established proce-
dure [9-11], which has also proved to be feasible, and
involves acceptable toxicity in children with hemato-
logic malignancies [10]. Although reports concerning
haplo-SCT for pediatric solid tumors are still anec-
dotal, a potential graft-versus-tumor (GVT) effect in
such cases has been discussed [12-14].
Considering the mentioned findings, we studied
the influence of high-dose131I-MIBG treatment fol-
lowed by reduced intensity conditioning (RIC) with
haplo-SCT in a series of consecutive RRNB patients
that, to the best of our knowledge, constitute the larg-
est cohort of such patients treated with this combined
approach.PATIENTS AND METHODS
Patient Population
The treatment used was designed for RRNB
patients aged 1-18 years who develop resistant disease
at any time. This study was approved by the LundUni-
versity Ethical Review Board For Research Involving
Humans (DNr 385/2005), and informed consent was
obtained from all parents/guardians.Mobilization and Processing of Peripheral Blood
Progenitor Cells
At the time the treatment protocol was developed,
it was suggested that the mobilization of peripheral
blood progenitor cells is more effective in male donors
[15,16]. To be able to harvest the optimal number of
CD341 cells, which is particularly important because
of additional cell loss caused by further processing of
the graft, we chose to transplant all our patients with
cells from an HLA haploidentical father. Typing was
performed at the 2-digit level for HLA class I and at
the allelic level for HLA class II. Donor peripheralblood progenitor cells were mobilized with recombi-
nant human granulocyte-colony stimulating factor
(rhG-CSF). To remove T cells from the graft, a Clin-
iMACS system (Miltenyi Biotech, Bergisch-Gladbach,
Germany) was used to subject the harvested cells to
immunomagnetic selection of CD341 cells (the first
collection) and to immunomagnetic depletion of
CD31 cells (the second collection), as previously
described [17]. The first collection secured the optimal
number of CD341 cells with the lowest possible num-
ber of contaminating T lymphocytes, and the second
collection served primarily as the source of accessory
cells, allowing a certain number of CD31 cells. The
target dose was set at $10  106 CD341 cells and
#1  105 CD31 cells per kilogram of recipient body
weight.Culture of Mesenchymal Stem Cells
To facilitate engraftment and reduce the risk of
GVHD, mesenchymal stem cells (MSCs) were trans-
planted directly after hematopoietic stem cell infusion
[18]. The MSCs were cultured as described elsewhere
[19]. Briefly, heparinized bone marrow (45-60 mL)
was aspirated from the iliac crest of the haploidentical
donor 4 weeks before transplantation. Ficoll-isolated
mononuclear cells were seeded in complete MSC
medium, which was changed after 3 days and weekly
thereafter. On the day of haplo-SCT, MSCs were har-
vested, washed, and resuspended in 0.9% saline sup-
plemented with 5% human serum albumin. Flow
cytometry showed expression of typical surface marker
profiles.Infusion of 131I-MIBG
On day –21 prior to haplo-SCT, all children
received a single 1-hour intravenous (i.v.) infusion of
131I-MIBG under thyroid protection with potassium
iodide and i.v. hydration. The patients were subse-
quently kept in a radiation-protected isolation room
until emissions met institutional regulations. Whole-
body (WB) activity was measured daily for 5-7 days,
and WB/SPECT imaging was performed on day –11.Conditioning and Posttransplant
Immunosuppression
RIC comprised fludarabine (Flu; 5 25 mg/m2 ev-
ery 24 hours, days –8 to –4), thiotepa (2 5 mg/kg, ev-
ery 12 hours, day –3), and melphalan (Mel; 2  60 mg/
m2 every 24 hours, days –2 and –1) [20]. The T cell re-
ceptor-targeted antibody muromonab-CD3 was ad-
ministered on days –8 to 115 as rejection prophylaxis.
A short course of posttransplantmycophenolatemofetil
(MMF) 600 mg/m2 bid was given on days –1 to128 as
GVHDprophylaxis. To reduce the risk of EBV-associ-
ated posttransplant lymphoproliferative disease, in vivo
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375 mg/m2 rituximab on day11.
Donor Lymphocyte Infusion (DLIs)
After terminating immunosuppression, DLIs were
planned to improve immune reconstitution and/or to
convert mixed chimerism (MC) to complete donor
chimerism (CC). The initial number of infused
CD31 lymphocytes was 2.5-5  104 cells/kg/dose.
The intention was to increase the dose of CD31 cells
if no GVHD occurred. For details, see Table 3. Blood
for a DLI was obtained from the donor on the day of
the infusion. No GVHD prophylaxis was given after
DLI.
Posttransplant Intrathecal Liposomal
Cytarabine
A patient with central nervous system (CNS)
relapse was given intrathecal liposomal cytarabine
every 4-6 weeks for up to 1 year after transplantation.
Engraftment, Immunological Reconstitution,
and Chimerism Analysis
Engraftment was defined as the first of 3 consecu-
tive days with an absolute neutrophil count (ANC)
.500/mL, and platelet recovery as the first of 3 consec-
utive days with transfusion-independent platelet count
.20,000/mL. Immunologic recovery was assessed
weekly for the first 3 months and thereafter once
over a period of 3-6 months. This was done by immu-
nophenotyping of peripheral blood mononuclear cells
with anti-CD3, anti-CD4, anti-CD8, anti-CD19, and
anti-CD16/CD56 monoclonal antibodies (mAbs).
Chimerism analysis was performed at the same time
points by amplification of variable number of tandem
repeats (VNTRs) as polymorphic genetic markers in
selected cell populations (T, B, and non-T/non-B
cells).
Supportive Care
No G-CSF was administered posttransplant. Pro-
phylactic voriconazole and valacyclovir were given for
6 months after transplantation. As oral prophylaxis
against Pneumocystis carinii pneumonia, trimetho-
prim-sulfamethoxazole was instituted for 6 months
following engraftment. Surveillance of cytomegalovi-
rus (CMV), adenoirus (AdV), Epstein-Barr virus
(EBV), and BK viral loads was achieved by PCR
performed weekly up to day 1100, and preemptive
therapy was initiated if increasing loads were detected.
Evaluation of Disease Response
In accordance with the International Neuroblas-
toma Response Criteria [21], evaluation of disease
markers and imaging studies in combination with
bilateral bone marrow aspirations and biopsies wereperformed at regular intervals of 4 to 6 weeks for the
first 6 months and thereafter every 3 to 6 months.RESULTS
Patient Characteristics
Between June 2005 and November 2005, 5
patients with stage IV RRNB were eligible for inclu-
sion in the study. These children (given unique patient
numbers NB01-NB05) had been intensively pre-
treated at the Department of Pediatric Oncology,
University Hospital, Lund, Sweden, 3 of them with
high-dose chemotherapy and ASCT. One of the pa-
tients had developed secondary acute myelogenous
leukemia (AML) that had been successfully treated.
One had achieved complete remission (CR) before
haplo-HSCT (CR 2), 3 were in partial remission
(PR), and 1 had progressive disease (progression).
The median interval between initial diagnosis and
haplo-HSCT was 3.9 years (Table 1).
Graft Composition
A median of 13  106 CD341 cells/kg were trans-
planted with a median of 0.98 105 graft-contaminat-
ing CD31 cells (Table 2). A median of 0.75  106
MSCs/kg were transplanted directly after HSC infu-
sion (Table 2).
High-Dose 131I-MIBG and RIC
High-dose 131I-MIBG treatment was feasible, and
infusion was done at a median dose of 10.9 mCi/kg,
corresponding to a median WB absorbed dose of 1.6
Gy (Table 3). The patient whose bone marrow was
infiltrated with NB cells at the time of treatment
(NB-02) had prolonged post-MIBG marrow aplasia
that persisted until the beginning of RIC, whereas
the other children recovered their blood counts before
start of conditioning. The RIC caused no serious
adverse effects.
Hematologic Recovery
Neutrophil engraftment was achieved in all 5 chil-
dren. The median time to ANC recovery was 13 days
(range: 11-16 days), and the median time to platelet
recovery, which occurred in 4 patients, was 12 days
(range: 11-37 days) (Table 2). One patient (NB-02)
rejected the graft on day 18, and an attempt to rescue
the graft by intensified immunosuppression and stem
cell boost failed. That child eventually recovered after
autologous backup.
Chimerism Analysis of T Cell Compartment
Although chimerism analysis was performed in dif-
ferent cell populations, DLI interventions were driven
by chimerism analysis of the T cell compartment
Table 1. Patient Characteristics
UPN
Sex age at
Dx/ haplo-
SCT (years) MYC-N
Primary
tumor and
metastases
First-line
treatment
Relapse # 1
(months after
Dx) localization
Second-line
treatment
Relapse # 2
(months after
Dx) localization
Third-line
treatment
Status prior to
haplo-SCT
(positive sites)
Time from Dx
to haplo-SCT
(months)
Outcome
(months)
NB-01 F 1.4/10.7 yes abd bone BM COJEC MEC +
AHCT RT
(20Gy) RA
61 paravert.,
dumbbell BM
RT, CADO
BuMel +
ASCT RA
110 paravert.,
bone, BM
RT TVD PR 3 BM 112 CR Relapse 7 m
DoD 12 m
NB-02 M 2.2/7.5 no adr bone BM
CNS
COJEC 131I-
MIBG Surgery
(tumorrest
CNS)
*46 Bone BM CADO TVD RT 60 CNS, BM,
abd
131I-MIBG progressive
disease BM +
CNS
64 Rejection day
+18 Auto-
back up
Disease
progression
DoD 5 m
NB-03 M 1.2/5.1 yes adr bone COJEC CADO
Surgery
BuMel +
ASCT RA
40 bone RT TV CR 2 47 CCR A&W 42
m
NB-04 M 6.8/8.1 no adr bone BM COJEC CADO
TVD Surgery
Never in
remission
before haplo-
SCT
PR 1 BM + bone 16 Alive 41 m with
disease,
ongoing DLI,
NB-05 M 5.0/7.0 no thor bone
BM
COJEC BuMel +
ASCT RT RA
18 dumbbell
CNS
RT TVD  3 PR 2 CNS +
paraspinal
24 CR A&W 42 m
UPN indicates unique patient number; Dx, diagnosis; haplo-SCT, haploidentical stem cell transplantation; MYCN, MYCN amplification; F, female; M, male; abd, abdominal; adr, adrenal gland; thor, thoracal; BM, bone
marrow; CNS, central nervous system; MEC, melphalan + etopside + carboplatin; Bu/Mel, busulfan + melphalan; 131I-MIBG, iodine-131-metaiodobenzylguanidine; CADO, carboplatin, doxorubicine, vincristine; TVD,
topotecan + vincristine + doxorubicine; TV, topotecan, vincristine; ASCT, autologous hematopoietic stem cell transplantation; RT, radiotherapy; Sx, surgery; RA, retinoic acid treatment; CR, complete remission; PR,
partial remission; CCR, continuous complete remission; A&W, alive and well; DoD, died of disease.
*Thirty months after diagnosis, the patient developed secondary AML M5 and was successfully treated with the conventional NOPHO-AML-93 protocol.
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Table 2. High-Dose 131I-MIBG, Graft Composition, and Engraftment
UPN
Total
administered
activity (mCi)
Administered
activity
(mCi/kg)
Whole-body
absorbed dose
(Gy)
CD34+
(106/kg)
CD3+
(105/kg)
MSC/kg
(106/kg)
ANC >0.5 
109/L (day)
Platelets >20 
109/L (day)
NB-01 186 6.97 1.6 12.5 1.43 1.0 + 13 +11
NB-02 270 10.5 2.4 11.0 0.45 0.4 +13 na
NB-03 277 13.5 1.5 22.6 0.98 0.3 + 11 +11
NB-04 266 11.4 2.1 9.6 0.96 0.9 + 16 +37
NB-05 263 10.9 1.5 17.9 0.98 0.75 + 11 +13
Median 266 10.9 1.6 12.5 0.98 0.75 +13 +12
131I-MIBG indicates iodine-131-metaiodobenzylguanidine; UPN, unique patient number; MSC, mesenchymal stem cells; ANC, absolute neutrophil
count.
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exhibited CC at the time of engraftment. Patient
NB-01 showed sustained CC at all time points. In
the remaining 3 patients, analysis of CD31 cells
revealed increasing MC after initial CC, which was
eventually converted to CC status.
Patient NB-03 displayed a decline to 93% donor
chimerism 6 weeks posttransplant and received DLI
treatment. Transient conversion to CC was achieved,
but despite that, only recipient T cells were detectable
9 weeks after transplant. Antithymocyte glubulin
(ATG) treatment was instituted, and the patient
successfully regained CC. In patient NB-04, donor2 4 6 8 10 12 14 1
Complete haplo donor MX
3%R 60%R7%R
CMV
CMV
AdV
ATG
60%R 5%R
CMV
BKV
CMV
NB-
01 
NB-
03 
NB-
04 
NB-
05 
NB-
02 
DLI <10
5
DLI >10
5
92%R 21%R 2%R
aGvHD
T-ce
(CD3+ cells/kg)
UPN
NB cells in the BM biopsy
Figure 1. Posttransplant chimerism analysis, virus reactivation, time of DLIs,
megalovirus reactivation; BKV, BK virus reactivation; AdV, adenovirus reactivat
ulin treatment; DLI, donor lymphocyte infusion; DoD, died of disease; A&W,
haplo-SCT.chimerism declined to 40% 6 weeks posttransplant,
and that child was given DLI and regained sustained
CC by week 10. Patient NB-05 showed a decline to
8%donor chimerism by week 5 posttransplant, despite
‘‘preemptive’’ DLI. Additional DLIs were given, and
the peripheral blood CD31 cells gradually increased
to CC by week 9. Chimerism analysis is presented in
Figure 1.Immune Reconstitution
Quantitative analysis was performed on T, B, and
NK lymphocytes from 4 of the patients. The median6 18 20 22 24 26 28
Weeks after Tx
ixed
%R  = % recipient T cells
Complete
recipient
aGvHD
aGvHD
BKV
aGvHD AdV
A&W
42 m
Alive 41 m
Progression
+38m
A&W
40 m
Relapse 7 m
DoD12 m
DoD 5 m
ll chimerism analysis
and outcomes. Abbreviations: UPN, unique patient number; CMV, cyto-
ion; aGVHD, acute graft-versus-host disease; ATG, antithymocyte glob-
alive and well; NB, neuroblastoma; BM, bone marrow; m, months after
110
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C
e
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l
s
/
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Figure 2. Immunological recovery (median values).
1082 Biol Blood Marrow Transplant 15:1077-1085, 2009J. Toporski et al.CD31 cell counts 2, 3, and 4 months posttransplant
were 175 (range: 60-1050), 265 (range: 90-2370), and
710 (range: 250-6160) cells/mL, respectively. NK cell
recovery was faster, with a median count of 420 (range:
220-1050) cells/mL 4 weeks after transplantation and
a median 1-year count of 320 (range: 190-1560)
cells/mL. B cell recovery was delayed until circulating
cells reappeared 4 months postgrafting, and the
median count 6 months after transplantation reached
180 (range: 50-280) cells/mL. Immune reconstitution
is shown in Figure 2. PCR analysis detected multiple
viral reactivations with no life-threatening clinical
symptoms occurred in 3 children and were successfully
treated preemptively (Figure 1).GVHD and DLI
None of the patients developed primary acute
GVHD (aGVHD). Four children with sustained
engraftment received DLIs at an initial dose of 2.5 
104 or 5  104 T cells/kg. The first infusion was per-
formed at the earliest on day 125, and at the latest
on day 149. Each patient had 2 to 5 DLIs. Two of
these 4 patients (NB-03 with imminent rejection and
NB-04 with posttransplant detection of NB cells in
bone marrow) received high-dose DLIs $1  105 of
CD31/kg (Table 3 and Figure 1). Secondary to
DLIs, all 4 children experienced aGVHD, which
either responded promptly to reinstitution of shortTable 3. Time of Posttransplant DLIs, Numbers of T Cells Used, a
UPN
Time of T cell add-backs
(days after TX)
No. of T cells
(104/kg)
NB-01 d49; d81; d136; d157 2.5; 5; 2.5; 5
NB-02 nd, * na
NB-03 d42; d56; d65; d78 5; 5; 25, 50
NB-04 d32; d46; d66; d80; d102 2.5; 5; 10; 50; 10
NB-05 d25; d38 5; 5
DLI indicates donor lymphocyte infusion; aGVHD, acute graft-versus-host dis
*Stem cell boost because of rejection on day +18.immunosuppression consisting of steroids and cyclo-
sporine (CsA) (3 patients) or subsided spontaneously
with no treatment (one patient). Characteristics of
the DLIs with regard to time point, T cell number,
and occurrence of secondary aGVHD are presented
in Table 3 and Figure 1. To date, no chronic GVHD
(cGVHD) has been observed in these patients.Outcome
The regimen of high-dose MIBG combined with
subsequent RIC was well tolerated, with no treat-
ment-related mortabilty (TRM). The most common
morbidity was viral reactivation and aGVHD second-
ary to DLI, both of which were easy to control by stan-
dard treatment. One patient (NB-02) rejected the
graft; bone marrow biopsy revealed NB cells, and he
was rescued by autologous backup, but died of pro-
gressive disease 5 months after haplo-SCT. One child
(NB-01) achieved CR but relapsed with bone metasta-
ses 7 months after transplantation; additional attempts
to control the disease with chemo-/radio-/immuno-
therapy failed, and the patient died 5 months later.
Another patient (NB-04) developed generalized bone
pain, and trephine biopsy revealed NB cell infiltration
in bone marrow 2 months posttransplant. The clinical
symptoms in this child disappeared after intensified
DLI with mild GVHD, and his general condition
gradually improved; all subsequent biopsies remainednd Acute GVHD Secondary to DLI
Secondary aGVHD
aGVHD
treatment/resolution
Grade III yes/yes
na na/na
Grade II yes/yes
Grade I no/yes
Grade II yes/yes
ease; UPN, unique patient number; nd, not done; na, not applicable.
Biol Blood Marrow Transplant 15:1077-1085, 2009 1083High-Dose 131I-MIBG with HSCTnegative up to January 2009, when a routine MIBG
scintigraphy revealed 2 new bone lesions in the ster-
num 38 months after haplo-SCT.
At present (manuscript submitted March 2009), 3
of the 5 children included in the study are alive (NB-
03, NB-04, NB-05), and show good clinical perfor-
mance and quality of life; for example, attending
school regularly. In short, they are doing well,
although patient NB-04 is being treated with local
irradiation and reinstitution of DLI, now 41 months
posttransplant. The other 2 children (NB-03 and
NB-05) have neither radiologic nor laboratory signs
of active disease 42 and 40 months, respectively, after
haplo-SCT (Figure 1).DISCUSSION
Neuroblastoma has an incidence of about 10 cases
per million children aged 0-14 years, and hence, it is
the most common pediatric extracranial solid tumor
[22]. It accounts for 7.8% of all childhood malignan-
cies, and it is the third leading cause of death because
of cancer [23]. The prognosis is particularly poor in
children suffering from metastatic disease combined
with other risk factors (e.g., age.1 year, amplification
of the MYCN oncogene, and unfavorable histology).
Even in cases involving complete remission followed
by high-dose chemotherapy and ASCT, the 3-year
EFS is less than 35% [24]. The prognosis is also very
dismal for high-risk patients who fail front-line ther-
apy, and it is unlikely that such individuals will benefit
from high-dose therapy [25]. Furthermore, in studies
of therapy-resistant NB patients [7,26], it was found
that survival was not improved by high-dose chemo-
therapy followed by ASCT and antibody-mediated
immunotherapy, retinoids, or immune modulation
with IL2. In contrast, allo-SCT offers potential advan-
tages over other treatment modalities. First of all, the
graft is always free of contaminating tumor cells,
although the contribution of peripheral graft-
contaminating NB cells to subsequent relapse (post-
ASCT) and overall survival (OS) remains controversial
[27-30]. Allo-SCT also results in recovery of properly
functioning NK cells that can correct any functional
defects that exist in their autologous counterparts,
which may provide a beneficial GVT effect. The
mechanisms of such influence are still unknown, but
it has been reported that NB cell immunogenicity is
very low, and HLA class I antigens are virtually unde-
tectable [31,32]. Accordingly, NB cells lacking expres-
sion of HLA class I molecules may constitute an
excellent target for NK cells [12,33-35]. For example,
administration or enhanced production of endogenous
cytokines or gene transfer might induce increased
expression of HLA class I on neuroblastoma cells[12,36,37], and thereby expose the tumor to both nat-
ural killer- (NK) and T cell-mediated attacks.
Another optionmight be to exploitT cell-mediated
cytotoxicity. Traditionally, it has been assumed that
NB cells, which apparently lack expression of HLA
class I, are not susceptible to the cytotoxic effect elicited
by T cells. However, a posttransplant cytokine storm
can cause NB cells to begin expressing HLA class I,
and thereby make them potential targets for T cells.
Therefore, we speculate thatGVHD-induced cytokine
release can have a similar effect. Moreover, it has been
suggested that someNBcellsmay be selected to survive
and progress by expressing either higher or lower levels
of MHC class I antigens to resist NK- or T cell-
mediated antitumor responses, respectively [36].
It has also been shown that NB cell lines are sus-
ceptible to killing by differentiated CD81CTL clones
in an MHC class-I nonrestricted manner [38]. Thus
tumor cells in vivo might be recognized and attacked
by haploidentical T cells after transplantation. Perhaps
activation of this mechanism can be applied to initiate/
enhance death pathways, so that they can subsequently
redirect nonspecific T cells of DLI origin toward NB
cells, and in that way be of therapeutic value.
The results of allo-SCTfromHLA-identical related
donors have been disappointing [6,8], but the associa-
tion between GVHD and effectiveness was not assessed
in the cited studies. All the patients in those investiga-
tions received standard GVHDprophylaxis, and the in-
cidence ofGVHDwas low among transplanted patients
with no scheduled DLI. Accordingly, apart from HLA
identity, that therapeutic settingwas oriented toward ef-
fective immunosuppression to avoid GVHD, which in
turn, might inhibit the GVT effect.
It is generally acknowledged that the GVT effect is
less pronounced when allo-SCT is performed in
a patient with a large tumor load. Therefore, to mini-
mize the pretransplant tumor burden, we administered
high-doseMIBG to all 5 of our patients. Our approach
with haplo-SCT followed by immunomodulation has
potential advantages, 1 of which is that the pharmaco-
logic GVHD prophylaxis is short compared to other
transplant modalities. Also, cotransplantation of do-
nor-derived mesenchymal stem cells is done primarily
to reduce the risk of GVHD. We chose that strategy
because our present patients’ grafts had relatively large
numbers of T cells, and we also wanted to facilitate and
enhance engraftment of HLA-incompatible hemato-
poietic cells [18]. Furthermore, low-dose DLI allows
induction of a potentially ‘‘controllable’’ GVHD,
which is beneficial, because HLA incompatibility
might enhance the GVT effect. Notably, all our
patients with sustained engraftment did in fact develop
DLI-induced GVHD, which might have contributed
to disappearance of disease and prevention of relapse.
The analysis of immunologic recovery revealed rapid
reappearance of potentially immunocompetent NK
1084 Biol Blood Marrow Transplant 15:1077-1085, 2009J. Toporski et al.and T cells, which might act as effector cells that are
responsible for the GVT effect. However, patient
NB-01 received immunosuppression for treatment of
GVHD, and that might have counterbalanced poten-
tial GVT and finally facilitated tumor regrowth.
Patient NB-04 showed substantial clinical improve-
ment after DLI-induced GvT, along with clearance
of NB cells from the bone marrow. He had no clinical
symptoms of the disease, but did have persistent non-
progressive bone metastases. The disease was stable up
to 38 months after transplantation, at which time 2
new lesions in the sternum were identified during elec-
tive control. This observation demonstrates that long-
lasting tumor control was achieved, but the tumor was
eventually able to escape immune surveillance. It also
suggests that, even quite some time after transplanta-
tion, additional measures are necessary to stimulate/
maintain/reinduce the GVT effect.
Research results have reported that infection with
human CMV confers resistance to cytotoxic agents
and protects against apoptosis in neuroectodermal
tumors [39]. The cited investigators also postulated
that CMV infection before or during tumorigenesis
might induce resistance in some NB patients. The
available clinical data confirming the relevance of
CMV infection in tumor cells concern malignant glio-
blastomas and prostate and colon cancer [40-43], but
CMV is also detectable in the vast majority of tumor
cell samples from NB patients (Dr. C. So¨derberg-
Naucler, Karolinska Institute, personal communica-
tion). If CMV-infected tumors are indeed targeted
by CMV-specific cytotoxic T lymphocytes (CTLs),
then the transplantation of a new, healthy immune sys-
tem from a haploidentical donor might induce an im-
munologic attack and eliminate tumor cells. This may
also be amechanism of effective elimination of residual
malignant cells that are primarily infected with the
virus. In our study, all of the patients, except NB-01,
and all of the donors were CMV-IgG positive at the
time of transplantation. Furthermore, 3 of the 4
patients with sustained engraftment had reactivated
CMV after transplantation. The ‘‘controllable’’ char-
acteristic of GVHD induced by DLI turned out to
be responsive to standard treatment, and no patient de-
veloped either life-threatening aGVHD or cGVHD.
Our treatment strategy is novel and unique,
because it is based on targeting of residual disease by
high-dose MIBG and RIC chemotherapy combined
with induction of a potentially long-lasting immuno-
mediated and a complex GVT effect achieved using
haploidentical donor immunocompetent cells. It
appears that this approach led to prolonged DFS in 2
of 5 children with otherwise incurable neuroblastoma,
although it is a matter of speculation whether the pro-
cedure was actually responsible for disappearance of
the tumors. Nevertheless, because it is highly unlikely
that a durable response can be obtained after givingonly a regimen of RIC or after 131I-MIBG treatment
alone, it seems reasonable to assume that the combina-
tion of the 2 procedures, together with
implementation of the GVT effect mediated by
haploidentical immune systems, contributed to the
promising outcomes in 2 of our 5 patients. Obviously,
this assumption must be confirmed in a larger study.ACKNOWLEDGMENTS
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